Sign in and upgrade to a paid plan to export insider/SAST/pledge disclosures as CSV.
Sign in and upgrade to a paid plan to export corporate actions as CSV.
Sign in and upgrade to a paid plan to export corporate actions as CSV.
Sign in and upgrade to a paid plan to export insider/SAST/pledge disclosures as CSV.
Sign in and upgrade to a paid plan to export corporate actions as CSV.
Sign in and upgrade to a paid plan to export bulk/block deals as CSV.

Gujarat Inject (Kerala) Ltd.

Healthcare · Pharmaceuticals & Biotechnology

BSE: 524238
₹9.40
▼ -0.28 (-2.89%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
69/100
Moderate
Valuation
99/100
Undervalued
Momentum
63/100
Neutral

QVM read Cheap on its own multiples Quality Moderate, Valuation Undervalued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹14 Cr
PE (TTM)
4.6
Industry median 36.1 (152 companies)
Price to Book
1.2
PEG (TTM)
0.0
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-61.9
Free Cash Flow
₹0 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
1620.00%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
194.79%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
151.64%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
2139.73%
as of March 31, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
414.46%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
0.47
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.00
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
20471.00
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
10.05%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
13.55%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
8.83%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
5.34%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
21.17%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
16.55%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

4 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.00)
  • Yes Return on equity is 15% or more (16.6%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

1 of 2 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

2 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Undervalued (below its own historical PE range))
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-2.9%
Low 9.2400 · High 9.7700
1W return
1.4%
Low 9.0500 · High 9.7900
1M return
-14.5%
Low 9.0500 · High 11.6500
52W return
-61.9%
Low 9.0500 · High 13.9500
Lifetime High ₹24.6800 (Dec. 24, 2024)
Lifetime Low ₹1.5500 (March 9, 2009)

Full price history and technicals →

EMA & SMA

Bullish0
Bearish6
5D
9.5
10D
9.6
20D
10.0
50D
11.1
100D
11.4
200D
10.7

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
100.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

9.47
Pivot
First resistance9.70
Second resistance10.00
Third resistance10.23
First support9.17
Second support8.94
Third support8.64
Day RSI40.3
Day MFI31.2
Day MACD-0.66
Day MACD signal-0.72

Beta

1M0.18
3M0.15
1Y0.15
3Y0.33

Price change analysis

↓ -14.5%
Over 1 Month
LowHigh
9.0511.65
↓ -61.9%
Over 3 Months
LowHigh
9.0513.95
↓ -61.9%
Over 6 Months
LowHigh
9.0513.95
↓ -61.9%
Over 1 Year
LowHigh
9.0513.95
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 4.6 (own history: 12.0–137.1)
Undervalued (below its own historical PE range)
Revenue (June 30, 2026)
₹12 Cr
Net profit (June 30, 2026)
₹1 Cr
Basic EPS (June 30, 2026)
₹0.8600

Ranks #172 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Dec 2024

Largest holders

Data unavailable.

Historical promoter holding

All shareholding details →

DateClientDealActionQuantityPriceExchange
31 Aug 2026 RAJNIKANT KISHORKUMAR SHAH Bulk Buy 900,000 11.4500 BSE
31 Aug 2026 PATADIYA CHIRAGKUMAR RAJESHKUMAR Bulk Sell 900,030 11.4500 BSE
16 Jun 2026 SURENDRA NEMCHAND SHAH Bulk Sell 100,000 113.0500 BSE
21 May 2026 NIRANJANKUMAR NAVRATANMAL JAIN Bulk Sell 122,500 101.0500 BSE
7 Jan 2026 PATADIYA CHIRAGKUMAR RAJESHKUMAR Bulk Buy 75,000 38.5500 BSE
6 Jan 2026 JIGNESH SHIVLAL MAKASANA Bulk Sell 80,000 36.8700 BSE
24 Dec 2025 BHUPENDRA J RATHOD (HUF) Bulk Sell 75,000 33.2000 BSE
5 Dec 2025 UMESHBHAI RAJESHBHAI PATADIYA Bulk Buy 86,284 28.6400 BSE
1 Dec 2025 UMESHBHAI RAJESHBHAI PATADIYA Bulk Buy 89,135 28.0200 BSE
23 Oct 2025 JIGNESH SHIVLAL MAKASANA Bulk Sell 100,000 20.5800 BSE

All bulk and block deals →

Corporate Announcements

All 3 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
1 Oct 2026 AGM/EGM Gujarat Inject Kerala Ltd - 524238 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
29 Sep 2026 AGM/EGM Gujarat Inject Kerala Ltd - 524238 - Shareholder Meeting / Postal Ballot-Outcome of AGM
25 Sep 2026 Company Update Gujarat Inject Kerala Ltd - 524238 - Intimation To Shareholders Regarding Sub-Division / Split Of Equity Shares From Face Value Of ?10/- Each To ?1/- Each - Physical Share Certificate(S) No Longer Valid.

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.00)
  • Comfortable interest coverage (20471.0x)
  • Strong revenue growth YoY (414.5%)

Weaknesses

  • Tight liquidity (Current Ratio 0.47)

Opportunities

  • PEG below 1 (0.01) -- earnings growth outpacing its own valuation
  • PE below 15 (4.6) relative to a typical growth business

Threats

  • Down 61.9% over the past year

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Gujarat Inject (Kerala) Ltd.

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.